Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LAB

Standard BioTools Inc

Feb 12 • 04:00PM ET

1.11

-0.08 -6.72 %

Healthcare • Medical Devices • USA • NASD

Peers: TMO DHR A ILMN BIO QGEN TECH TWST PACB DNA

| Held by: VTI IWM VXF ARKG IBB IWN VTWO SCHA IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	4.15%	Shs Outstand	383.61M	Perf Week	-10.48%
Market Cap	426.87M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	390.88%	Shs Float	368.61M	Perf Month	-31.90%
Enterprise Value	259.36M	PEG	-	EPS next Q	-0.05	Inst Own	75.80%	Short Float	2.66%	Perf Quarter	-6.72%
Income	-128.25M	P/S	3.31	EPS this Y	60.16%	Inst Trans	-1.56%	Short Ratio	5.84	Perf Half Y	-15.27%
Sales	128.83M	P/B	1.07	EPS next Y	42.98%	ROA	-17.93%	Short Interest	9.79M	Perf YTD	-13.28%
Book/sh	1.04	P/C	2.19	EPS next 5Y	42.89%	ROE	-24.63%	52W High	1.72 -35.47%	Perf Year	-18.08%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	12.51% 11.61%	ROIC	-30.40%	52W Low	0.92 20.65%	Perf 3Y	-45.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.13% 8.27%	Gross Margin	46.52%	Volatility	5.55% 6.05%	Perf 5Y	-80.00%
Dividend TTM	-	EV/Sales	2.01	EPS Y/Y TTM	52.28%	Oper. Margin	-83.21%	ATR (14)	0.09	Perf 10Y	-80.96%
Dividend Ex-Date	-	Quick Ratio	4.14	Sales Y/Y TTM	-17.37%	Profit Margin	-99.55%	RSI (14)	27.75	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	4.38	EPS Q/Q	-24.97%	SMA20	-20.83%	Beta	1.37	Target Price	1.55
Payout	-	Debt/Eq	0.07	Sales Q/Q	-56.52%	SMA50	-22.59%	Rel Volume	1.20	Prev Close	1.19
Employees	818	LT Debt/Eq	0.06	Earnings	Feb 24 AMC	SMA200	-13.86%	Avg Volume	1.68M	Price	1.11
IPO	Feb 10, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-107.85% 8.62%	Trades		Volume	1,999,844	Change	-6.72%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Downgrade	TD Cowen	Buy → Hold	$1.55
Feb-27-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Feb-10-26 07:00AM	Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-30-26 09:09AM	Standard BioTools Completes Sale of SomaLogic to Illumina (GlobeNewswire)
Jan-08-26 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue (GlobeNewswire) +20.31%
Nov-19-25 11:30AM	Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry (Business Wire)
Nov-10-25 12:15PM	Illumina Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks (PR Newswire)
05:31PM	Loading…
Nov-04-25 05:31PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 08:01AM	Earnings To Watch: Standard BioTools Inc (LAB) Reports Q3 2025 Result (GuruFocus.com)
Oct-21-25 07:00AM	Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 (GlobeNewswire)
Sep-03-25 09:15AM	Illumina Protein Prep launches to drive greater proteomic insights for improved drug discovery and development (PR Newswire)
Aug-11-25 07:00PM	Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:09PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:25AM	What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 05:30PM	Doximity (DOCS) Q1 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Loading…
Aug-06-25 07:00AM	Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study (GlobeNewswire)
Jul-21-25 07:00AM	Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 (GlobeNewswire)
Jun-26-25 08:07AM	Illumina Stock May Benefit From New Agreement to Acquire SomaLogic (Zacks)
Jun-25-25 12:16AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire)
Jun-23-25 07:13AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire) +17.14%
07:05AM	Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina (GlobeNewswire)
06:58AM	Illumina to buy SomaLogic for up to $425M (MedTech Dive)
May-30-25 07:00AM	Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series (GlobeNewswire)
May-09-25 05:00PM	Labrador Gold Announces Resignation of Director Kai Hoffmann (GlobeNewswire) +8.41%
May-07-25 08:26AM	Q1 2025 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
03:20AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.83%
04:01PM	Standard BioTools Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 10:10AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 07:00AM	Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 (GlobeNewswire)
04:05PM	Loading…
Apr-22-25 04:05PM	Sight Sciences Appoints Gary Burbach to its Board of Directors (GlobeNewswire) +6.72%
07:00AM	Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 (GlobeNewswire)
Feb-27-25 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.68%
07:09AM	Q4 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
02:22AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Feb-26-25 06:52PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance) -7.14%
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 10:54AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.26%
Feb-12-25 07:00AM	Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 (GlobeNewswire)
Jan-13-25 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue (GlobeNewswire) +26.38%
Jan-08-25 07:00AM	Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine (GlobeNewswire)
Dec-19-24 08:00AM	Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 08:00AM	Standard BioTools Appoints Alex Kim as Chief Financial Officer (GlobeNewswire)
Oct-31-24 11:00AM	Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
08:01AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 05:20PM	Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.43%
04:15PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-21-24 09:03PM	Millennium Management LLC Acquires Shares in Standard BioTools Inc (GuruFocus.com)
Oct-16-24 08:00AM	Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 (GlobeNewswire)
Oct-03-24 04:56AM	Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-24-24 08:00AM	Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan 11K Platform (GlobeNewswire) +5.35%
Sep-18-24 08:00AM	Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) (GlobeNewswire)
Aug-26-24 08:00AM	Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-23-24 06:03PM	Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors (Barrons.com) +9.74%
Aug-06-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 09:14AM	Q2 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -36.61%
Jul-31-24 09:57PM	LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024 (InvestorPlace)
05:40PM	Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Standard BioTools Announces Senior Leadership Changes (GlobeNewswire)
04:01PM	Standard BioTools Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:01AM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire)
May-28-24 04:01PM	Standard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers (GlobeNewswire)
May-22-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-24 08:00AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49% +7.59%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Partners Master Fund, L	Director	Dec 04 '25	Buy	1.45	150,000	217,020	72,100,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 02 '25	Buy	1.42	125,000	177,512	71,875,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 03 '25	Buy	1.44	75,000	108,037	71,950,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Nov 25 '25	Buy	1.30	7,550,000	9,838,405	71,750,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 24 '25	Buy	1.43	150,000	214,875	64,200,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 20 '25	Buy	1.30	450,000	586,260	64,050,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 19 '25	Buy	1.28	350,000	448,910	63,600,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 18 '25	Buy	1.23	275,000	339,405	63,250,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 13 '25	Buy	1.20	450,000	541,395	62,500,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 14 '25	Buy	1.24	250,000	309,800	62,750,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 17 '25	Buy	1.22	225,000	275,580	62,975,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 12 '25	Buy	1.19	375,000	445,838	62,050,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 11 '25	Buy	1.20	300,000	358,800	61,675,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 10 '25	Buy	1.17	275,000	321,915	61,375,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 07 '25	Buy	1.12	225,000	252,765	61,100,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Sep 09 '25	Buy	1.29	100,000	128,920	60,875,000	Sep 11 09:03 PM
Casdin Partners Master Fund, L	Director	Sep 04 '25	Buy	1.28	250,000	319,350	60,775,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Sep 03 '25	Buy	1.27	250,000	316,400	60,525,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Aug 22 '25	Buy	1.26	200,000	252,680	59,950,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 25 '25	Buy	1.24	200,000	248,180	60,150,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 26 '25	Buy	1.26	125,000	157,938	60,275,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 15 '25	Buy	1.22	150,000	183,210	59,750,000	Aug 15 09:18 PM
Casdin Partners Master Fund, L	Director	Aug 14 '25	Buy	1.21	133,220	161,543	59,600,000	Aug 15 09:18 PM
Casdin Partners Master Fund, L	Director	Aug 13 '25	Buy	1.31	75,000	98,280	59,466,780	Aug 15 09:18 PM
Kim Hanjoon Alex	Chief Financial Officer	May 23 '25	Sale	0.94	1,428	1,344	930,286	May 28 05:54 PM
Mackay Sean	SVP & Chief Business Officer	May 23 '25	Sale	0.94	13,217	12,437	843,076	May 28 05:52 PM
Egholm Michael	President & CEO	May 23 '25	Sale	0.94	5,473	5,150	2,741,191	May 28 05:44 PM
Kim Hanjoon Alex	Chief Financial Officer	May 22 '25	Sale	1.00	1,355	1,358	931,714	May 27 08:33 PM
Egholm Michael	President & CEO	May 22 '25	Sale	1.00	5,116	5,126	2,746,664	May 27 08:28 PM
Mackay Sean	SVP & Chief Business Officer	May 21 '25	Sale	1.03	12,838	13,223	868,829	May 23 06:13 PM
Mackay Sean	SVP & Chief Business Officer	May 22 '25	Sale	1.00	12,536	12,561	856,293	May 23 06:13 PM
Mackay Sean	Officer	May 23 '25	Proposed Sale	0.94	13,217	12,441		May 23 04:19 PM
Kim Hanjoon Alex	Officer	May 23 '25	Proposed Sale	0.94	1,428	1,344		May 23 04:18 PM
Egholm Michael	Officer	May 23 '25	Proposed Sale	0.94	5,473	5,152		May 23 04:09 PM
Egholm Michael	President & CEO	May 21 '25	Sale	1.03	4,719	4,861	2,751,780	May 22 08:03 PM
Kim Hanjoon Alex	Chief Financial Officer	May 21 '25	Sale	1.03	1,407	1,449	933,069	May 22 08:01 PM
Egholm Michael	Officer	May 22 '25	Proposed Sale	1.00	5,116	5,126		May 22 04:20 PM
Mackay Sean	Officer	May 22 '25	Proposed Sale	1.00	12,536	12,560		May 22 04:13 PM
Kim Hanjoon Alex	Officer	May 22 '25	Proposed Sale	1.00	1,355	1,358		May 22 04:07 PM
Kim Hanjoon Alex	Officer	May 21 '25	Proposed Sale	1.03	1,407	1,451		May 21 04:22 PM
Mackay Sean	Officer	May 21 '25	Proposed Sale	1.03	12,838	13,240		May 21 04:16 PM
Egholm Michael	Officer	May 21 '25	Proposed Sale	1.03	4,719	4,867		May 21 04:13 PM
Egholm Michael	President & CEO	Apr 04 '25	Option Exercise	0.00	196,512	0	2,832,518	Apr 08 04:04 PM
Kim Hanjoon Alex	Chief Financial Officer	Apr 04 '25	Option Exercise	0.00	70,183	0	962,281	Apr 08 04:03 PM
Casdin Partners Master Fund, L	Director	Feb 28 '25	Buy	1.06	4,820,959	5,134,321	58,846,780	Mar 04 08:19 PM

Open in Screener

WGS

GeneDx Holdings Corp

Feb 12 • 04:00PM ET

90.67

-0.77 -0.84 %

Healthcare • Diagnostics & Research • USA • NASD

WGS GeneDx Holdings Corp daily Stock Chart

Peers: ILMN GH QDEL NTRA EXAS MYGN TWST CDNA CRSP VERV

| Held by: VTI ARKK IWM VXF ARKG IWO VTWO SCHA VHT TSME

Index	RUT	P/E	1503.65	EPS (ttm)	0.06	Insider Own	12.31%	Shs Outstand	28.89M	Perf Week	7.84%
Market Cap	2.62B	Forward P/E	161.25	EPS next Y	0.56	Insider Trans	-15.45%	Shs Float	25.35M	Perf Month	-17.45%
Enterprise Value	2.58B	PEG	1.65	EPS next Q	0.10	Inst Own	107.70%	Short Float	14.27%	Perf Quarter	-35.19%
Income	2.08M	P/S	6.52	EPS this Y	434.55%	Inst Trans	-2.91%	Short Ratio	6.18	Perf Half Y	-26.35%
Sales	402.19M	P/B	8.96	EPS next Y	-58.60%	ROA	0.46%	Short Interest	3.62M	Perf YTD	-30.29%
Book/sh	10.12	P/C	16.90	EPS next 5Y	97.58%	ROE	0.84%	52W High	170.87 -46.94%	Perf Year	27.76%
Cash/sh	5.37	P/FCF	169.41	EPS past 3/5Y	70.39% 96.65%	ROIC	0.52%	52W Low	55.17 64.35%	Perf 3Y	580.26%
Dividend Est.	-	EV/EBITDA	73.89	Sales past 3/5Y	12.91% 14.24%	Gross Margin	64.89%	Volatility	6.07% 7.16%	Perf 5Y	-89.35%
Dividend TTM	-	EV/Sales	6.42	EPS Y/Y TTM	102.37%	Oper. Margin	2.74%	ATR (14)	7.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.59	Sales Y/Y TTM	50.50%	Profit Margin	0.52%	RSI (14)	36.36	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.71	EPS Q/Q	13.59%	SMA20	-5.90%	Beta	2.03	Target Price	170.00
Payout	-	Debt/Eq	0.39	Sales Q/Q	51.86%	SMA50	-26.11%	Rel Volume	1.04	Prev Close	91.44
Employees	1000	LT Debt/Eq	0.37	Earnings	Feb 23 BMO	SMA200	-17.13%	Avg Volume	585.17K	Price	90.67
IPO	Nov 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.87% 11.58%	Trades		Volume	606,978	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$155
Oct-20-25	Initiated	Canaccord Genuity	Buy	$155
Jul-09-25	Initiated	Piper Sandler	Overweight	$110
May-15-25	Initiated	Guggenheim	Buy	$88
May-09-25	Upgrade	Jefferies	Hold → Buy	$80
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Feb-11-26 09:05AM	TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the Worlds Most Influential Leaders in Health (Business Wire)
Feb-03-26 08:00AM	GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026 (Business Wire)
Jan-15-26 11:24AM	Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Jan-12-26 09:56AM	GeneDx Partners With Komodo Health to Advance Rare Disease Research (Zacks) -11.92%
07:30AM	GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance (Business Wire)
08:30AM	Loading…
Jan-08-26 08:30AM	GeneDx and Komodo Health Partner to Build the Worlds Most Complete Longitudinal Rare Disease Dataset (Business Wire)
Jan-07-26 08:30AM	GeneDx Announces GenomeDx Prenatal, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care (Business Wire)
Jan-06-26 08:30AM	GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care (Business Wire)
Jan-05-26 08:30AM	GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025 (Business Wire)
Dec-30-25 11:47PM	What Do Analysts Think About GeneDx Holdings Corp. (WGS)? (Insider Monkey)
08:00AM	GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference (Business Wire)
Dec-15-25 08:30AM	JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year (Business Wire)
Dec-09-25 07:58AM	Cathie Wood Dumps Tesla Again, Pours Millions Into This Tech Gaint (GuruFocus.com)
Dec-05-25 10:11AM	TSLA: Cathie Wood Dumps Millions in Tesla and Meta Shares (GuruFocus.com)
Nov-30-25 03:20PM	HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
11:42PM	Loading…
Nov-15-25 11:42PM	Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat (Insider Monkey)
Nov-06-25 08:00AM	GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting (Business Wire)
Nov-04-25 08:00AM	GeneDx to Participate in Upcoming Investor Conferences (Business Wire)
Oct-28-25 07:45AM	GeneDx Holdings Corp. (WGS) Q3 Earnings and Revenues Surpass Estimates (Zacks) +5.21%
06:30AM	GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Oct-27-25 01:56PM	Will This Genetic Testing Name's Profit Soar 950%? Earnings Are On Deck. (Investor's Business Daily)
09:27AM	GeneDx Holdings Corp (WGS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-24-25 09:40AM	Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-22-25 04:00PM	Four Reasons To Watch This 'Breakthrough' Stock Including 954% Expected Growth (Investor's Business Daily)
Oct-20-25 09:34AM	Apple upgraded, Rivian downgraded: Wall Street's top analyst calls (The Fly) +5.04%
Oct-15-25 09:15AM	Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot (PR Newswire)
Oct-14-25 08:00AM	GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer (Business Wire)
05:01AM	InnovAge (INNV) Surges 8.6%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 08:00AM	GeneDx to Partner with Floridas Sunshine Genetics Network, Launching Nations First State-Backed Genomic Newborn Screening Program (Business Wire)
Oct-09-25 08:00AM	GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program (Business Wire)
08:00AM	Loading…
Oct-08-25 08:00AM	GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting (Business Wire)
Oct-07-25 08:00AM	GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025 (Business Wire)
Oct-01-25 04:01PM	GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award (Business Wire) +5.29%
Sep-30-25 08:00AM	GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth (Business Wire) -5.43%
Sep-25-25 08:00AM	GeneDx Infinity Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference (Business Wire)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks)
08:00AM	GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors (Business Wire)
Sep-15-25 12:20PM	Here's Why Ensign Group Shares Are Attracting Investors Now (Zacks)
Sep-12-25 02:13PM	Here's Why Pediatrix Medical Shares Are Attracting Investors Now (Zacks)
Sep-05-25 04:16PM	ZoomInfo, International Money Express, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-28-25 08:14AM	PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down (Zacks)
Aug-21-25 10:12AM	Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges (Zacks)
Aug-19-25 09:48AM	MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up (Zacks)
Aug-13-25 08:22AM	Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand (Zacks) +5.76%
Aug-12-25 08:27AM	EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up (Zacks) +5.31%
08:25AM	Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise (Zacks)
08:22AM	EYE Stock Gains on Q2 Earnings and Revenue Beat, '25 View Up (Zacks)
08:21AM	VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up (Zacks)
Aug-11-25 12:20PM	Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates? (Zacks) +5.15%
08:27AM	Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract (Zacks)
07:53AM	TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up (Zacks)
Aug-08-25 12:44PM	Hims Stock Gets Booted Off IBD 50 While Other Volatile Names Hang On (Investor's Business Daily)
08:47AM	TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market (Zacks)
Aug-07-25 09:55AM	Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross? (Zacks)
Aug-06-25 09:05AM	Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls (Zacks)
08:30AM	GeneDx to Participate in Upcoming Investor Conferences (Business Wire)
Aug-04-25 09:55AM	IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand (Zacks) +6.64%
Aug-01-25 07:51AM	Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb (Zacks)
Jul-31-25 04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
07:59AM	Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down (Zacks)
Jul-30-25 08:00PM	Why GeneDx Holdings Stock Crushed It Again Today (Motley Fool) +12.78%
Jul-29-25 07:13PM	Why GeneDx Holdings Stock Blasted 8% Higher Today (Motley Fool) +8.09%
09:49AM	WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View (Zacks)
08:54AM	Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang? (Zacks)
07:40AM	GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates (Zacks)
06:30AM	GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jul-28-25 12:41PM	Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter? (Zacks) +6.36%
12:38PM	Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings? (Zacks)
12:10PM	Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again (Zacks)
09:27AM	Earnings To Watch: GeneDx Holdings Corp (WGS) Reports Q2 2025 Result (GuruFocus.com)
09:26AM	Will Exome and Genome Growth Boost WGS' Q2 Earnings? (Zacks)
07:56AM	IDEXX to Release Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-24-25 11:11AM	Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat? (Zacks)
10:15AM	Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? (Zacks)
Jul-23-25 10:00AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-22-25 12:11PM	WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up? (Zacks)
10:00AM	GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-21-25 08:05AM	DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance? (Zacks)
Jul-17-25 09:55AM	Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect? (Zacks)
Jul-16-25 09:42AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Jul-15-25 09:02AM	Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings? (Zacks)
Jul-11-25 08:02AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks) -5.01%
Jul-10-25 08:30AM	GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025 (Business Wire) -5.41%
08:19AM	Here's Why You Should Retain CONMED Stock in Your Portfolio for Now (Zacks)
Jun-30-25 02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-27-25 07:45AM	Why GeneDX Stock Surged Higher This Week (Motley Fool)
Jun-25-25 08:30AM	GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics (Business Wire)
Jun-24-25 04:25PM	Why GeneDx, An IBD 50 Stock, Has Skyrocketed 36% Over The Past Two Days (Investor's Business Daily) +14.04%
07:31AM	GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last? (Zacks)
Jun-23-25 03:17PM	GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability (Business Wire) +18.97%
08:30AM	Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases (Business Wire)
Jun-17-25 08:59AM	Zacks Industry Outlook Highlights CVS Health, BrightSpring Health Services and GeneDx (Zacks)
Jun-16-25 11:09AM	3 Medical Services Stocks Capitalizing on the Healthcare AI Boom (Zacks)
09:35AM	Here's Why ENSG Shares Are Attracting Prudent Investors Now (Zacks)
Jun-03-25 11:44AM	Ensign Enhances Presence With 3 New Acquisitions in 2 States (Zacks)
Jun-02-25 12:22PM	Here's Why You Should Hold Cigna Stock in Your Portfolio for Now (Zacks)
May-30-25 11:50AM	Danaher Partners With AstraZeneca to Support Precision Medicine (Zacks)
09:32AM	COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down (Zacks)
09:31AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
May-29-25 09:55AM	Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know (Zacks)

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dechairo Bryan	Chief Operating Officer	Feb 04 '26	Sale	85.70	5,961	510,874	0	Feb 06 04:19 PM
Dechairo Bryan	Chief Operating Officer	Feb 01 '26	Option Exercise	0.00	9,374	0	9,374	Feb 03 07:30 PM
Dechairo Bryan	Chief Operating Officer	Feb 02 '26	Sale	99.53	3,413	339,682	5,961	Feb 03 07:30 PM
Bryan Dechairo	Officer	Feb 02 '26	Proposed Sale	99.20	9,374	929,900		Feb 02 05:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '26	Option Exercise	0.00	754	0	9,485	Feb 02 04:33 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '26	Sale	93.99	317	29,794	9,168	Feb 02 04:33 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Jan 29 '26	Option Exercise	0.00	3,874	0	18,111	Feb 02 04:30 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Jan 29 '26	Sale	94.00	1,653	155,375	16,458	Feb 02 04:30 PM
Kevin Feeley	Officer	Jan 29 '26	Proposed Sale	98.10	24,155	2,369,700		Jan 29 07:27 PM
Katherine Stueland	Officer	Jan 29 '26	Proposed Sale	98.09	94,495	9,268,700		Jan 29 07:25 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 16 '25	Option Exercise	0.00	7,197	0	12,586	Dec 18 05:20 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 16 '25	Sale	143.87	3,855	554,616	8,731	Dec 18 05:20 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Dec 16 '25	Option Exercise	0.00	18,750	0	25,094	Dec 18 05:18 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Dec 16 '25	Sale	143.89	10,857	1,562,185	14,237	Dec 18 05:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '25	Option Exercise	0.00	2,462	0	6,655	Dec 11 04:31 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '25	Sale	159.28	1,266	201,648	5,389	Dec 11 04:31 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Dec 09 '25	Option Exercise	0.00	6,547	0	9,983	Dec 11 04:29 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Dec 09 '25	Sale	159.28	3,639	579,620	6,344	Dec 11 04:29 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 01 '25	Option Exercise	0.00	717	0	4,570	Dec 03 04:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 01 '25	Sale	162.54	377	61,276	4,193	Dec 03 04:18 PM
RUCH JOSHUA	Director	Nov 24 '25	Sale	160.37	38,000	6,093,967	11,941	Nov 26 04:13 PM
RUCH JOSHUA	Director	Nov 24 '25	Proposed Sale	160.37	38,000	6,093,969		Nov 24 04:30 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Option Exercise	0.00	3,874	0	5,594	Oct 31 04:42 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Sale	136.54	2,158	294,654	3,436	Oct 31 04:42 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '25	Option Exercise	0.00	753	0	4,145	Oct 31 04:41 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '25	Sale	136.54	388	52,978	3,757	Oct 31 04:41 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Sep 30 '25	Sale	108.17	12,858	1,390,911	1,720	Oct 01 04:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 30 '25	Option Exercise	32.67	1,246	40,707	10,001	Oct 01 04:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 30 '25	Sale	108.38	6,609	716,261	3,392	Oct 01 04:18 PM
Kevin Feeley	Officer	Sep 30 '25	Proposed Sale	107.73	5,805	625,400		Sep 30 08:04 PM
Katherine Stueland	Officer	Sep 30 '25	Proposed Sale	107.74	16,425	1,769,600		Sep 30 08:04 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '25	Sale	121.47	3,728	452,850	8,755	Sep 18 06:05 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Sep 16 '25	Option Exercise	0.00	18,750	0	25,079	Sep 18 06:04 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Sep 16 '25	Sale	121.47	10,501	1,275,585	14,578	Sep 18 06:04 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '25	Option Exercise	0.00	6,546	0	9,986	Sep 11 04:07 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '25	Sale	128.06	3,657	468,297	6,329	Sep 11 04:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '25	Option Exercise	0.00	2,462	0	6,558	Sep 11 04:06 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '25	Sale	128.05	1,272	162,886	5,286	Sep 11 04:06 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 01 '25	Option Exercise	0.00	717	0	4,474	Sep 03 06:31 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 02 '25	Sale	125.81	378	47,556	4,096	Sep 03 06:31 PM
Ryan Jason	Director	Aug 27 '25	Sale	127.30	38,072	4,846,708	103,284	Aug 27 09:01 PM
Ryan Jason	Director	Aug 27 '25	Sale	129.65	1,150	149,093	11,904	Aug 27 09:01 PM
Ryan Jason	Director	Aug 27 '25	Proposed Sale	127.22	39,222	4,990,000		Aug 27 05:20 PM
Casdin Partners Master Fund, L	Affiliate	Aug 22 '25	Proposed Sale	120.90	500,000	60,451,950		Aug 22 07:14 PM
Casdin Capital, LLC	Director	Aug 22 '25	Sale	120.90	500,000	60,451,950	3,007,164	Aug 22 06:55 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '25	Option Exercise	0.00	753	0	4,145	Jul 31 04:06 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '25	Sale	105.31	388	40,860	3,757	Jul 31 04:06 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '25	Option Exercise	0.00	3,874	0	5,594	Jul 31 04:04 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '25	Sale	105.31	2,154	226,838	3,440	Jul 31 04:04 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 09 '25	Option Exercise	32.67	1,245	40,674	8,670	Jul 11 04:04 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 09 '25	Sale	93.00	5,278	490,854	3,392	Jul 11 04:04 PM
Stueland Katherine	Chief Executive Officer	Jul 09 '25	Sale	93.00	3,220	299,460	1,720	Jul 11 04:03 PM
Stueland Katherine	Chief Executive Officer	Jul 01 '25	Sale	90.94	9,657	878,181	4,940	Jul 03 02:32 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 01 '25	Sale	91.12	1,344	122,471	7,425	Jul 03 02:31 PM
Kevin Feeley	Officer	Jul 01 '25	Proposed Sale	92.32	5,805	535,900		Jul 01 07:53 PM
Katherine Stueland	Director	Jul 01 '25	Proposed Sale	92.31	16,425	1,516,200		Jul 01 07:53 PM
Casdin Eli	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	20,518	Jun 23 05:50 PM
Meister Keith A.	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	20,129	Jun 23 05:50 PM
Ryan Jason	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	13,054	Jun 23 05:48 PM
Leproust Emily M.	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	21,276	Jun 23 05:45 PM
PFENNIGER RICHARD C JR	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	41,506	Jun 23 05:45 PM
RUCH JOSHUA	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	29,723	Jun 23 05:44 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '25	Option Exercise	0.00	18,750	0	25,098	Jun 18 04:14 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '25	Sale	64.77	10,501	680,181	14,597	Jun 18 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 16 '25	Sale	64.77	3,729	241,539	8,769	Jun 18 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '25	Option Exercise	0.00	2,462	0	6,567	Jun 11 04:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '25	Sale	72.55	1,266	91,848	5,301	Jun 11 04:05 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '25	Option Exercise	0.00	6,547	0	9,987	Jun 11 04:04 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '25	Sale	72.55	3,639	264,009	6,348	Jun 11 04:04 PM
Kevin Feeley	Officer	Jun 09 '25	Proposed Sale	72.55	5,009	363,400		Jun 09 07:23 PM
Katherine Stueland	Officer	Jun 09 '25	Proposed Sale	72.55	14,139	1,025,800		Jun 09 07:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 01 '25	Option Exercise	0.00	718	0	4,475	Jun 03 05:30 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 02 '25	Sale	71.26	370	26,366	4,105	Jun 03 05:30 PM
Kevin Feeley	Officer	Jun 02 '25	Proposed Sale	71.35	370	26,400		Jun 02 08:55 PM
Meister Keith A.	Director	May 14 '25	Buy	60.16	50,000	3,007,997	3,058,629	May 16 04:00 PM
Meister Keith A.	Director	May 08 '25	Buy	56.01	100,000	5,600,994	3,008,629	May 12 07:46 PM
PFENNIGER RICHARD C JR	Director	May 02 '25	Option Exercise	0.00	918	0	28,582	May 05 04:48 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '25	Option Exercise	0.00	753	0	3,725	May 01 07:46 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '25	Sale	113.09	388	43,879	3,337	May 01 07:46 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '25	Option Exercise	0.00	3,874	0	5,594	May 01 07:44 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '25	Sale	113.09	2,154	243,596	3,440	May 01 07:44 PM
Kevin Feeley	Officer	Apr 29 '25	Proposed Sale	113.14	388	43,900		Apr 29 09:52 PM
Katherine Stueland	Director	Apr 29 '25	Proposed Sale	113.09	2,154	243,600		Apr 29 09:51 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Apr 14 '25	Proposed Sale	101.04	250,000	25,260,000		Apr 14 08:00 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Option Exercise	32.67	1,246	40,707	17,242	Apr 10 04:12 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Sale	92.18	15,516	1,430,334	1,726	Apr 10 04:12 PM
Stueland Katherine	Chief Executive Officer	Apr 09 '25	Sale	89.62	46,594	4,175,817	1,720	Apr 10 04:11 PM
Feeley Kevin	Officer	Apr 09 '25	Proposed Sale	91.80	14,270	1,310,000		Apr 09 05:36 PM
Stueland Katherine	Officer	Apr 09 '25	Proposed Sale	87.99	46,594	4,100,000		Apr 09 05:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Option Exercise	0.00	16,250	0	24,742	Mar 28 04:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	95.61	8,746	836,211	15,996	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Option Exercise	0.00	80,000	0	94,865	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Sale	95.62	46,551	4,451,084	48,314	Mar 28 04:07 PM
Kevin Feeley	Officer	Mar 26 '25	Proposed Sale	95.61	8,746	836,200		Mar 26 06:36 PM
Katherine Stueland	Director	Mar 26 '25	Proposed Sale	95.62	46,551	4,451,200		Mar 26 06:34 PM
Stueland Katherine	Chief Executive Officer	Mar 16 '25	Option Exercise	0.00	18,750	0	25,424	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 17 '25	Sale	96.71	10,559	1,021,146	14,865	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 13 '25	Sale	89.44	1,078	96,420	6,674	Mar 17 09:51 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 17 '25	Sale	96.71	3,749	362,565	8,492	Mar 17 09:50 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 13 '25	Sale	90.05	402	36,202	5,044	Mar 17 09:50 PM

Open in Screener

TNYA

Tenaya Therapeutics Inc

Feb 12 • 04:00PM ET

0.6836

+0.0039 0.57 %

Healthcare • Biotechnology • USA • NASD

TNYA Tenaya Therapeutics Inc daily Stock Chart

Peers: EDIT CRSP NTLA BEAM BMRN SRPT BLUE SGMO PSTX ABEO

| Held by: VTI IBB VXF BTEC IBBQ BIB AVTM

Index	-	P/E	-	EPS (ttm)	-0.79	Insider Own	6.14%	Shs Outstand	216.51M	Perf Week	-8.85%
Market Cap	148.00M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-25.00%	Shs Float	203.21M	Perf Month	-9.93%
Enterprise Value	103.22M	PEG	-	EPS next Q	-0.12	Inst Own	15.24%	Short Float	12.28%	Perf Quarter	-51.86%
Income	-94.26M	P/S	-	EPS this Y	53.91%	Inst Trans	3.22%	Short Ratio	5.27	Perf Half Y	-20.61%
Sales	0.00M	P/B	1.35	EPS next Y	23.53%	ROA	-76.77%	Short Interest	24.95M	Perf YTD	-3.92%
Book/sh	0.51	P/C	2.63	EPS next 5Y	-	ROE	-96.44%	52W High	2.35 -70.91%	Perf Year	-23.83%
Cash/sh	0.26	P/FCF	-	EPS past 3/5Y	9.39% -15.57%	ROIC	-103.05%	52W Low	0.36 89.89%	Perf 3Y	-75.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.74% 9.99%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.68%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.64	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.48	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.64	EPS Q/Q	58.29%	SMA20	-10.12%	Beta	3.20	Target Price	3.83
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	-19.48%	Rel Volume	0.95	Prev Close	0.68
Employees	97	LT Debt/Eq	0.10	Earnings	Nov 10 BMO	SMA200	-30.23%	Avg Volume	4.73M	Price	0.68
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.03% -	Trades		Volume	4,489,866	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-24	Initiated	William Blair	Outperform
Nov-30-23	Initiated	Leerink Partners	Outperform	$7
Jun-15-22	Initiated	H.C. Wainwright	Buy	$25

Jan-19-26 08:01AM	Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 (Insider Monkey)
Jan-12-26 04:23AM	Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech (Insider Monkey)
Jan-09-26 08:30AM	Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Dec-12-25 12:16AM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -37.50%
Dec-11-25 04:02PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Loading…
04:01PM	Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC (GlobeNewswire)
04:01PM	Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy (GlobeNewswire)
Nov-10-25 07:00AM	Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +11.72%
Nov-08-25 11:25AM	Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire)
Nov-04-25 05:30PM	Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 (GlobeNewswire)
Oct-09-25 04:05PM	Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference (GlobeNewswire) +10.38%
Oct-02-25 04:05PM	Tenaya Therapeutics to Participate in Upcoming October Investor Conferences (GlobeNewswire)
Sep-18-25 04:05PM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.20% +6.82%
Sep-02-25 04:05PM	Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire) +9.26%
Aug-31-25 10:15AM	Tenaya Therapeutics Presents Interim Data from MyClimb Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 (GlobeNewswire)
10:30AM	Loading…
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +8.62%
Aug-08-25 08:00AM	Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-07-25 05:15AM	Clinical trial supply chains in the US navigate pharma tariffs (Clinical Trials Arena)
Aug-06-25 04:30PM	Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-25 08:30AM	Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed (GlobeNewswire)
May-15-25 09:00PM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +12.74%
May-13-25 08:30AM	Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting (GlobeNewswire)
May-07-25 04:05PM	Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-25 02:07PM	Tenaya Therapeutics Presents Interim Data from RIDGE Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 (GlobeNewswire)
Apr-01-25 12:26PM	Tenaya highlights HCM gene therapy interim data at ACC 2025 (Clinical Trials Arena)
Mar-31-25 10:00AM	Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK -1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting (GlobeNewswire) -11.25%
Mar-28-25 10:43AM	Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey) -7.14%
Mar-25-25 11:27AM	Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey) -6.61%
09:18AM	Top 3 Insider Stock Buys in March-Are They Still Good in April? (MarketBeat)
08:45AM	Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function (TipRanks)
08:30AM	Loading…
Mar-24-25 08:30AM	Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models (GlobeNewswire) +9.96%
Mar-19-25 08:30AM	Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-10-25 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +11.14% +6.78%
Mar-03-25 11:19PM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -6.25% -53.53%
04:10PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 08:30AM	Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine (GlobeNewswire)
Jan-13-25 09:16AM	Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Dec-17-24 07:00AM	Tenaya Therapeutics Reports Promising Early Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire) -51.04%
Dec-16-24 04:30PM	Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 (GlobeNewswire)
Nov-25-24 08:30AM	Tenaya Therapeutics Doses First Patient in RIDGE-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +24.37%
Nov-19-24 08:00AM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +10.19%
Nov-06-24 04:05PM	Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +12.11%
Nov-03-24 06:11AM	Morgan Stanley Predicts Up to 670% Jump for These 2 Strong Buy Stocks (TipRanks)
Oct-17-24 04:30PM	Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM (GlobeNewswire) +22.86% -5.12%
Sep-03-24 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investment Conferences (GlobeNewswire) -5.60%
Aug-08-24 04:05PM	Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.10%
Jun-27-24 05:00PM	Tenaya Therapeutics Announces Research Leadership Updates (GlobeNewswire) +8.09% +5.44%
Jun-18-24 04:30PM	Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit (GlobeNewswire)
May-16-24 12:21PM	Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating (MT Newswires)
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-14-24 10:54PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-02-24 05:00PM	Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Mar-26-24 07:19AM	20 Countries with the Highest Heart Disease Deaths Per Capita (Insider Monkey)
Mar-20-24 05:32AM	Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +8.17%
Mar-18-24 10:53PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -6.02%
04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-27-24 04:30PM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-24 09:55AM	Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross? (Zacks) +9.00%
08:30AM	Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications (GlobeNewswire)
Feb-09-24 09:55AM	Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet (Zacks) +10.72%
Feb-08-24 08:00AM	Tenaya Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire) +16.06%
Jan-26-24 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-03-24 08:30AM	Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.28%
Nov-21-23 04:30PM	Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-08-23 04:05PM	Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-26-23 08:30AM	Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) -5.67%
Oct-09-23 08:30AM	Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting (GlobeNewswire)
Oct-05-23 08:30AM	Tenaya Therapeutics Doses First Patient in the MyPeak-1 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire)
Oct-02-23 05:30PM	Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration (GlobeNewswire) -5.24%
Sep-21-23 04:05PM	Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences (GlobeNewswire) +6.06%
Aug-31-23 04:05PM	Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire) -5.38%
Aug-09-23 04:05PM	Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Aug-02-23 04:05PM	Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference (GlobeNewswire)
May-30-23 09:06AM	With 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interest (Simply Wall St.)
May-15-23 09:55AM	Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade (Zacks)
May-11-23 08:50AM	Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.65%
May-10-23 04:19PM	Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 08:00AM	Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting (GlobeNewswire) +12.36%
07:09AM	We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-02-23 07:50AM	Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 (GlobeNewswire) -11.30%
Apr-25-23 06:35AM	The 7 Best Biotech Stocks for Personalized Medicine Investors (InvestorPlace) -5.77%
Apr-23-23 04:02PM	3 Penny Stocks to Buy for 100% Returns (InvestorPlace)
Apr-21-23 04:05PM	Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire) +22.79%
Apr-20-23 02:46PM	Why This Nasdaq Stock Caught Fire This Week (Motley Fool) +26.08%
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +17.16%
Mar-08-23 04:01PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.96% -12.57%
Feb-07-23 05:17PM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-26-23 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-09-23 07:00AM	Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones (GlobeNewswire)
Dec-21-22 06:12AM	Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop (Simply Wall St.)
Dec-07-22 04:30PM	Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors (GlobeNewswire)
Dec-02-22 06:36PM	IRobot and Acrivon Stock See Action From Activist Investors (Barrons.com)
Nov-28-22 08:30AM	Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +7.11%
Nov-24-22 05:54AM	Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely (Simply Wall St.)

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COLUMN GROUP III GP, LP	10% Owner	Feb 11 '26	Sale	0.68	4,056,573	2,761,715	2,348,183	Feb 12 05:19 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 10 '26	Sale	0.82	343,717	280,507	4,253,298	Feb 12 05:19 PM
COLUMN GROUP III-A, LP	10% Owner	Feb 11 '26	Proposed Sale	0.68	742,663	504,788		Feb 11 05:57 PM
COLUMN GROUP III, LP	10% Owner	Feb 11 '26	Proposed Sale	0.68	657,627	446,989		Feb 11 05:52 PM
COLUMN GROUP III-A, LP	10% Owner	Feb 10 '26	Proposed Sale	0.79	1,591,090	1,256,961		Feb 10 05:25 PM
COLUMN GROUP III, LP	10% Owner	Feb 10 '26	Proposed Sale	0.79	1,408,910	1,113,038		Feb 10 05:06 PM
Higa Tomohiro	SVP, Finance	Nov 17 '25	Sale	1.33	1,367	1,818	93,971	Nov 17 08:34 PM
Tingley Whittemore	Chief Medical Officer	Nov 17 '25	Sale	1.33	2,877	3,826	169,926	Nov 17 08:34 PM
Ali Faraz	Chief Executive Officer	Nov 17 '25	Sale	1.33	3,126	4,158	299,666	Nov 17 08:33 PM
Higa Tomohiro	SVP, Finance	Aug 18 '25	Sale	1.25	2,962	3,711	95,338	Aug 18 09:00 PM
Tingley Whittemore	Chief Medical Officer	Aug 18 '25	Sale	1.25	5,053	6,331	172,803	Aug 18 08:59 PM
Ali Faraz	Chief Executive Officer	Aug 18 '25	Sale	1.25	14,533	18,210	302,792	Aug 18 08:58 PM
Whittemore Tingley	Officer	Aug 18 '25	Proposed Sale	1.25	5,053	6,331		Aug 18 08:57 PM
Faraz Ali	Officer	Aug 18 '25	Proposed Sale	1.25	14,533	18,210		Aug 18 08:56 PM
Higa Tomohiro	SVP, Finance	May 16 '25	Sale	0.44	1,390	615	98,300	May 16 07:07 PM
Tingley Whittemore	Chief Medical Officer	May 16 '25	Sale	0.44	2,937	1,300	171,856	May 16 07:07 PM
Ali Faraz	Chief Executive Officer	May 16 '25	Sale	0.44	3,189	1,412	317,325	May 16 07:07 PM
Higa Tomohiro	SVP, Finance	Mar 10 '25	Sale	0.54	2,482	1,336	99,690	Mar 10 09:44 PM
Tingley Whittemore	Chief Medical Officer	Mar 10 '25	Sale	0.54	7,398	3,983	174,793	Mar 10 09:43 PM
Ali Faraz	Chief Executive Officer	Mar 10 '25	Sale	0.54	9,741	5,245	320,514	Mar 10 09:42 PM
Whittemore Tingley	Officer	Mar 10 '25	Proposed Sale	0.54	7,398	3,983		Mar 10 09:41 PM
Faraz Ali	Officer	Mar 10 '25	Proposed Sale	0.54	9,741	5,245		Mar 10 09:40 PM
COLUMN GROUP III GP, LP	10% Owner	Mar 05 '25	Buy	0.70	35,714,284	24,999,999	49,313,559	Mar 07 07:14 PM
GOEDDEL DAVID V	Director	Mar 05 '25	Buy	0.70	35,714,284	24,999,999	49,313,559	Mar 07 07:14 PM

LAB

Standard BioTools Inc

WGS

GeneDx Holdings Corp

TNYA

Tenaya Therapeutics Inc

Upgrade your FINVIZ experience